AFT grows by 7% as Maxigesic rollout progresses

28 May 2021 - Deborah Wilkes

Premium

AFT Pharmaceuticals reported sales up by 7% to NZD113 million (USD81.6 million) in the 12 months ended 31 March 2021. The New Zealand company said the tablet version of its Maxigesic combination painkiller was available in 43 countries at the end of the 12-month period, up from 28 a year earlier.

Click tags below for more information on topics:

AFT COVID-19

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: